0
Yissum
Ações Integradas Nacionais
e Internacionais
Renée Ben-Israel, Vice Presidente,
Propriedade Intelectual
Yissum, Research Development Company of
The Hebrew University of Jerusalem, Ltd
Curitiba, Paraná, Brasil - 19-22 Maio 2015
FORTEC – 2015
1
Roteiro
Introdução
A Universidade Hebraica de Jerusalém
Yissum
Conclusões
Modelos – 3 modelos de comercialisação
Israel
2
3
Eco-sistema de suporte
Israel: data
Area - Total 120,770 / 22,072 km2 (151st)8,019 / 8,522 sq mi - Water (%)~2% (1)
Population - 8,296,000 (2013 estimate) (1)
Density365,3/km2 (30th), 946.1/sq mi (1)
GDP (PPP)2013 estimate - Total $32,140 PPP dollars
Gross domestic product : 290.6 billion USD (2013) (1)
Education expenditures – 5.9% of GPD (1)
Gross domestic expenditure on R&D – 4,9% (2009) (2) (3)
Sources: (1)Wikipedia, (2)OECD (3) OECD average:2.3%
Alguns sucessos
Waze – the smart phone social GPS
“disk on key” – USB flash drive
Given Imaging – capsule endoscopy
Ituran - location & control of vehicles
Check Point - security systems
Netafim – drip irrigation systems
The cherry tomatoes
5
6
Israel’s Top University
HUJI
No. 1 in Israel
No. 5 in Asia-Pacific region
No. 59 worldwide
No. 27 worldwide in Computer Science
No. 38 worldwide in Natural Sciences &
Mathematics
* U of Texas Institute of Higher Education, Shanghai Jiaotong University 2013
Scale of Academic Excellence
Bar-Ilan
Univ.
Ben-Gurion
Univ.
Technion
Tel Aviv
Univ.
The Hebrew University
of Jerusalem
53
100-150
301-400
Weizmann
Inst.
93
78
O fenomeno
Dan Senor, Saul Singer, 2011
8
Yissum
Fundada em 1964
26 experts nas areas de:
Desenvolvimento de Negócios
Pesquisa Colaborativa
Patentes
Legal (contratos)
Admin e finanças
Chefiada por: Yaacov Michlin
Yissum - Estrutura Organizacional
Adv. Bob Trachtenberg
General Counsel
Yaacov Michlin, CEO
Intellectual
Propery (4)
Finance (5) Business
Development (11)Legal (3)
Adv. Martha Fredman
Deputy General Counsel
Renee Ben Israel
VP, IP
Tamar Gallily
Patent Attorney
Dr. Michal Levy
VP, Head of Business Development,
Agritech & Environment
Dr. Shoshi Keynan
VP, Head of Business Development,
Healthcare
Ariela Markel
VP Business Development, Healthcare
Tamir Huberman
VP Business Development Computer
Science & Director of IT
Dr. Dov Reichman, VP Business
Development – Chemistry & Physics
Irina Abramzon, Business Development
Agri-Tech & Veterinary
Sharon Cohen
CFO
Avi Katz
Controller
Dr. Itzik Goldwaser
VP, Head of Research Collaborations
Business
Intelligence
Gustavo Fuchs
Business and IP
Intelligence Officer
Dana Gavish Fridman
Director of Marketing
Marketing
10
Onde a Ciência Significa Negócios – estrutura legal
Business leaders
Business-oriented
organization
Non-profit organization
11
Yissum – modelos de negócios
Pesquisa
Colaborativa
Empresa de
Spin Off
Pesquisadores
Laboratório
de Recursos
Tecnologias
Disponíveis
Contrato de
Licença
Yissum – modelos de negócios
Licenciamento a companhias
existentes
Colaborações com indústria
Pesquisa mantida nos
laboratórios universitários
Criação de novas companhias
Criação de companhia incubada
Income Distribution
40%
20%
40%
Royalty Distribution
Researcher
Researcher's Laboratory
Yissum & Huji
66,6%
33.3%
Incubator Founder's Equity Distribution
Researcher
Yissum
50,0%50.0%
Start-Up Founder's Equity Distribution
Researcher
Yissum
16
51 anos de Transferência de Tecnologias
8,537 patents
2,403
inventions
705 licenses
88 spin-offs
Produtos baseados em tecnologias da Universidade Hebraica e
comercializados pela Yissum geram > $2B anuais em vendas
17
Propriedade Intelectual
2013 Snapshot170 new inventions
47 new patents granted
Intellectual Property at HUYissum owns all IP
developed at HU
Researchers receive
40-60% of revenues
Life Science & Biotechnology
54%
Materials &
Chemistry
24%
Agriculture,
Food &
Nutrition 9%
Micro & Opto Electronics
5%
Computer Science &
Engeneering10%
A variety
of new
inventions
Humanities 2%
Yissum’s Biotech Product Pipeline:
Vekacia ® (Novagali)
Cyclokat ® (Novagali)
Ladostigil, (Avraham)
BC819 (Biocancell)
Anti Angiogenic (Tiltan)
MRX4 (Morria)
Acc. Levodopa (Intec)
LABR-312 ( Biorest)
CatioProst ® (Novagali)
Apocell (Enlivex)
CCS/C (Nasvax)
EPOdure (Medgenics)
AB103 (Atox Bio)
Cortiject ® (Novagali)
Phase I Phase II Phase III
MRX6 (Morria)
Acc. Zalepon (Intec)
Acc. Baclofen (Intec)
PRX105 (Protalix)
BL7040 (Bioline Rx)
Protexia (Pharmathene)
MM-002 (Moebius)
6
2
2010
159
Israel*Yissum
Phase III
Phase II
Phase I
*Source: ILSI Database - 2010
Promitil (Lipomedix)
19
88 Spin-Offs desde 1964
20
Alcance Global
27
$16M - Acordos de Colaboração – longo
prazo
7 ongoing projects
9 research projects
10 research projects
2 research projects
1 research project
2 research projects
4 ongoing projects
1 research project
Lockheed Martin and Yissum sign R&D collaboration
06/10/2014, 12:34Gali WeinrebThe Hebrew University collaboration includes quantum and material sciences.Lockheed Martin Israel Ltd. and Yissum Research Development Company Ltd., the technology transfer company of the Hebrew University of Jerusalem, have signed an agreement to conduct joint collaborative research. The collaboration will focus on basic and applicable scientific research in areas such as quantum information sciences and material sciences, and other areas
29
Yissum cria de 8-10
novas companhias e
licencia ~60 tecnologias
anualmente
Centenas de novos
empregos são criados
para a força de trabalho
capacitada
$16 M são gerados do
trabalho de pesquisa
colaborativa com a
indústria
Benefícios adicionais
Iniciativas comerciais:
Além do Vale da Morte
Academic
Projects/
Grants
Baby Seed Kamin/
Nofar
Magneton,
Incubators
Independent
Companies
Extensive Long Term
Collaboration
102 projects
approved for
Yissum’s
internal
program
Such as
Roche,
Google, etc
Funding through the
Office of the Chief
Scientist
The Financial Valley of
Death
30
Integra
Holdings/ Ag-
Bio Fund
HUJI Projects
+ New!
Collaboration
with Shaare
Zedek Hospital
32
Modelo I –Ações integradas: NovagaliIncubadora Europea
Gustavo Fuchs – Business & IP Intelligence Officer
Um jovem pesquisador
1990
Dr. Simon Benita, pesquisador na area de nano-delivery em drogas de CNS (Central Nervous System) contra Alzheimer
Notou que o mesmo sistema poderia ser adequadono de transmissão de medicamentos do sistemaocular
33
34
Ophthalmology Market: The Need
Growing market Numerous unmet needs Increasing number of new molecules
But
Current formulation limitations:
Poor Tolerability Low Bioavailability Many hurdles for lipophilic drugs Inability to reach the back of the
eye to treat retinal diseases
The need for an Ophthalmic DD Expert
Prof. Simon BenitaUniversity of JerusalemExpert in Drug Delivery
Prof. Marco Fabrizio SaettoneUniversity of PisaExpert in Ophthalmic DD
1992 – Proof of Principle
36
1996 - First Patent Filed (Granted 1999)
37
First offer to establish an Incubator
Company
An Israeli investor proposes to invest
$300k to start an incubator to develop
the technology
Conversations with a Biotech Science Park based near Paris – a better proposal
38
The next international collaboration
1997 – Incubator Project
66 biotech companies
20 academic research labs
17 shared-access technology platforms and technical facilities
86,538 m2 of real estate
€272,25 million in equity funding raised by Genopole®
companies
942 patents filed by campus companies
26 molecules or biotherapies in development or on the market,
from the regulatory preclinical phase through to market
launch
2 186 direct jobs
2000 – Novagali was funded
by Prof. Benita and Yissum
2000 - Licensing Agreement
2000 – 2004 - First Investments
2000 - 3.78 M€
2003 - 5 M€
2004 - 9 M€
41
• To strengthen the valuable assets of the company• To conduct Phase I/II clinical trials• To invest in laboratory, pilot and production
equipment.
2001 - Second Patent Filed (Granted 2003)
42
Novagali today
43
Novagali Pharma Company today cont.
~ 45 employees including 13 doctors of science, medicine or pharmacy
Located in Evry (Paris suburb – Genopôle)
5 rounds of financing for a total amount of € 81m
Listed in Euronext in 2010 and acquired by Santen Japan in Dec. 2011
Formulation Analytical & QC Scale Up Pilot Manufacturing
pre-clinical Studies Clinical Development Regulatory Commercialization
44
Products in the Pipeline
45
46
Renée Ben-Israel, VP Intellectual Property
Yissum, Research Development Company of
The Hebrew University of Jerusalem, Ltd
LIGHTING THE WAY WITH CUTTING-EDGE SOLUTIONS
Modelo II
Qlight Nanotech, Ltd
De 2009 a 2015 – a tragetória
Best Nanotechnology Company Of The Year" Award Given To Qlight
Nanotech At The NanoIsrael 2014 Conference (Yahoo, HUJI)
47
Nosso herói:
48
Prof Uri Banin
the Institute of Chemistry and
the Center for Nanoscience and
Nanotechnology,
The Hebrew University of
Jerusalem,
Givat Ram, Jerusalem, 91904,
Israel
Com participações internacionais
49
Laboratório Prof Banin – áreas de
estudo
Nanoscience and Nanotechnology:
Basic Science and Applications of Nanoparticles Synthesis and characterization of novel semiconductor nanocrystals
and nanostructures and their assemblies
Size dependent optical and electronic properties of nanocrystals
Single nanostructure microscopy and spectroscopy
Alternative energy solutions using nanoparticles
Lasers and optical devices based on colloidal semiconductor
nanostructures
Biological, medical and sensing applications of nanocrystals
Non linear optical properties of semiconductor nanocrystals and
nanorods
Electrical Transport studies on single nanorods and nanocrystal
arrays
50
Prof Banin e Qlight Nanotech
Pesquisador regular na universidade
Em busca de soluções a problemas da
arte existente
Quando apresentou o projeto de pesquisa,
era considerado um tanto futurístico
em 2009, depois de ter colaborado com
outras companhias de nanotecnologia,
Banin decide iniciar sua própria
companhia => Yissum
51
Modelo de negócio:
Uma start-up utilisando somas
governamentais (Israel OCS - Office of
Chief Scientist) por um lado, e por outro
uma colaboração estratégica com uma
companhia (Merck KGaA), baseada em
suas invenções na área do uso de
nanocristais em display e aplicações na
área de iluminação
52
Modelo de negócio
A lógica da criação da start-up:
Escolher um modelo de negócio mais
adequado(*) e a aplicação mais “quente” do
mercado.
Qlight/Merck colocaram um foco no mercado
de LCD (liquid crystal display)/iluminação para
substituir a tecnologia existente
Na realidade existe toda uma área (a
plataforma) não desenvolvida pela Merck
(*) Best use of the technology
53
Israel - políticas de apoio, histórico
1968 – criação do cargo de “Cientista Chefe”
do Ministério da Indústria e Comércio com o
mandato de subsidiar projetos de pesquisa
científica conduzidos por companhias (setor
privado)
Objetivo: desenvolver indústrias baseadas
em ciência, com orientação para exportação
para promover a criação de empregos e
ampliar e explorar a infra- estrutura científica
existente e promover os RH de alta qualidade
Israel - políticas de apoio, incentivos
à indústria
Incentivos fiscais à indústria:
Subsídios de até 50% dos custos de
pesquisa em companhias existentes
66% em start-ups
Israel - políticas de apoio
Programas específicos:
Magnet, Nofar, Tnufa – para incentivar pesquisa
conduzida em consórcios em estágios pré-
competitivos
Kamin – para levar projetos inventivos à fase de
prova de conceito
Criação de incubadoras tecnológicas
Programas de colaboração internacional -
bilaterais e multilaterais
OCS – Office of the Chief Scientist – Israel
NOFAR
Israeli government incentives for Industrial
application of Academic Research
Designed to support applied academic research in specific
technological areas (biotechnology, nanotechnology,
medical devices, water & energy storage), in order to
adapt it to relevant applications in the industry, and
promotes the transfer of these technologies to the
industry. Project's budget is up to
USD 130,000 for a period of 12 months. Grants are up to
90% of the approved budget, to be complemented by the
industrial company accompanying the project.
57
Parceria: por que a Merck?
Merck KGaA possue uma posição de
liderança no mercado global de Liquid Crystals
com >60% do mercado. Merck tambem está
investindo significantemente, para se tornar a
maior fornecedora de materiais da próxima
geração de tecnologia de display & lightning a
serem competitivas com outras tecnologias como
por exemplo: OLED (organic LED).
Na realidade a ligação da Universidade com a
Merck existe ainda antes da criação da Qlight
Nanotech.
58
59
Quantum dot semiconductor nanoparticles for energy-efficient
light sources and displays.
The technology improves picture quality in brightness and colour
range.
As origens: uma tecnologia revolucionária
Nova tecnologia
Problemas com tecnologia, arte-prévia
Shells, core shells, multi shells => muita arte-
prévia
Uri Banin estava ciente da situação => procura
novas soluções
De quantum dots a quantum “rods”
Rods possuem caracteristicas superiores em
aplicações relevantes como de direcionamento
(inclusive conseguiu desenvolver “self
assembly”)
61
Estado da arte 2009
62
For example:
A quantum dots technology company, their
business model consisting of:
•Sales of Quantum Dot Concentrate™ material
•Technology licensing of component designs,
like our Quantum Dot Enhancement Film (QDEF)™,
to industrial supply chain partners
Propriedade Intelectual
Patents cover everything from the fundamentals of
quantum dot construction to component and
manufacturing designs. This extensive portfolio is the
result of collaborations between Nanosys and
prestigious universities such as Massachusetts
Institute of Technology (MIT), Lawrence Berkeley
National Labs and Hebrew University, as well as
industry collaborations with companies like Philips-
Lumileds and Life Technologies.
63
Quantum dot
Quantum dot é uma partícula semicondutora
medindo de alguns a dezenas de
nanometros, que é capaz de emitir luz
monocromática de alta qualidade.
64
Quantum rods
Quantum dots convencionais se
parecem com particulas (pontos), mas
os nanocristais produzidos pela
Qliquits/Merck se parecem com rods
(linhas)
Portanto, foram denominados
"quantum rods“.
65
Vantagens
Economia no consumo de energia (o tempo de
uso da bateria do celular é reduzido
consideravelmente)
Produção dos produtos rezultantes a custo muito
reduzido
Em termos de reprodução das cores, quantum
rods podem reproduzir nivel de 100% do leque
das cores em padrões NTSC*.• Produção de côr – sistema americano
( National Television System Committee)
66
Propriedade Intelectual
No início:
Patentes da Yissum sendo exclusivamente
licenciadas a Merck
Com o tempo – patentes conjuntas,
desenvolvidas por inventores de ambas
partes
Patentes de plataforma e patentes de uso
especifico
67
ABEF – Active Brightness Enhancement Film
Qlight está devenvolvendo "ABEF“(*) , uma
pelicula ótica contendo nanomateriais da
Qlight
A pelicula proporciona mais um valor unico: um
aumento significante da claridade em comparação
aos produtos existentes, numa simples estrutura
(*)Active Brightness Enhancement Film
68
69
ABEF: Brightness enhancement technology
for screens and lighting
Qlight’s LCD’s quantum rods
70
The latest samples (May 2014). An LCD using the
left) and Qlight’s LCD)conventional method
71
Capabilidades do Lab do Prof.
Uri Banin do Instituto de Quimica
identificadas
Modelo de negocio: Yissum cria a
start up, Qlight Nano
Investimento por um líder global
Merck KGaA.
Uma bolsa Nofar do governo
israelense (OCS).
Boa cobertura de patentes
O resultado: Uma start up de
successo fundada em 2009, hoje
com laboratórios e escritorios em
Jerusalem, com 24 empregados.
Resumindo:
Congratulations to Qlight!
“Company of The Year 2014” in the Nanotechnology Field
72
Modelo IIIOs maravilhosos tomatinhos (e algunspimento)
74
1948 – Israeli farming takes it’s baby steps.
The Israeli government’s strategic decision:
Investment in Agricultural Research
1973 – Prof. Nachum Keidar and his research
group from the Hebrew University, Faculty of
Agriculture receives government funds
The story of the Israeli Seed Industry
H RabinovitchN Keidar, RIP Y Elkind
75
A revolutionary approach was taken by the Hebrew University’s researchers: taking the ripening inhibiting genes: rin & nor from industrial tomatoes and inserted them into fresh tomatoes using traditional breeding
They created a long shelf life tomato
Till then tomatoes were able to stay fresh for 3-4 days from picking and now – they kept fresh. It could stay for 2-3 weeks!
This changed the tomatoes world’s industry
The story of the Israeli Seed Industry
76
Daniela was born.
The world-famous tomato variety for its tempting
red color and long shelf life.
The story of the Israeli Seed Industry
• Could grow in different
climates around the world.
77
1982 – The big
commercial
success.
The story of the Israeli Seed Industry
Yissum commercialized the new hybrid to Hazera
(Israeli seed company).
78
The story of the Israeli Seed Industry
At the time Hazera was in a bad financial situation and they wanted someone to invest in the company, but no one wanted to do so.
In 1982 – Daniela became a BIG world commercial success. Until then Hazera supplied seeds only for local use. From that point they became a big seed exporter.
79
The global seed industry dramatically
changed by this discovery.
A new world standard for fresh tomatoes was
established.
The breeding group from the Hebrew
University became very popular among the
seed companies.
The story of the Israeli Seed Industry
80
All Israeli seed companies wanted to be part in the celebration.
Yissum, together with Profs. Keidar & Rabinowitch decided to give license to each company on a new variety as they creates them.
The seeds companies from their point of view understood the huge potential in investing in this group and they all started to fund different breeding programs.
All the research is done in the Faculty of Agriculture in the Hebrew University.
The story of the Israeli Seed Industry
81
Yissum signed licensing agreements with multiple
companies.
The agreements include a section ensures that the
breeding and the production will continue to be
done in Israel.
The story of the Israeli Seed Industry
Supporting your local
industry – a strategic
goal.
82
Until today the group developed 1,700 different Hybrid combinations and about 150 are commercialized
Resistance to different diseases.
Growing on one branch.
Cherry tomatoes.
The story of the Israeli Seed Industry
83
In 2006 world giant Vilmorin finalized it’s holdings in Hazera
Genetics, when 40% of the Israeli company’s revenues
relayed on Hebrew University varieties.
Epilogue (part I)
84
Israeli firm Zeraim Gedera was sold to world leader
Syngenta in 2007. In 2010 Syngenta’s revenues from HUJI
varieties topped $40 Million.
Epilogue (part II)
85
In 2010 Israeli company A.B. Seeds was sold to De-Ruiter.
Later on Monsanto’s vegetable Seeds Division.
De-Ruiter was purchased by Monsanto and the Israeli
branch became
Epilogue (part III)
Know the research Group
Phytopathology
Plant Biology
Breeding Projects
Breeding Supporting Technologies
Technology Transfer
Over $50 of BonTom seeds - over 5,000 kg annually
The International Presence
"Breed IT" Comprehensive Information System
Obrigada pela atenção!
Visite nosso site
www.yissum.co.il
Top Related